Mesoblast Investor Presentation — February 2018

| 1 22/23 Febr uary 2018 Nasdaq : MESO ASX: MSB Mesoblast Phase 3 Cell Therapy Trial for Acute Graft Versus Host Disease ( aGVHD) Successfully Achieves Primary Endpoint Presented at BMT/Tandem, February 21, 2018